Background: Immune infiltration of the tumor microenvironment has been associated with improved survival for some patients with solid tumors. The precise makeup and prognostic relevance of immune infiltrates across a broad spectrum of tumors remain unclear. Methods: Using mRNA sequencing data from The Cancer Genome Atlas (TCGA) from 11 tumor types representing 3485 tumors, we evaluated lymphocyte and macrophage gene expression by tissue type and by genomic subtypes defined within and across tumor tissue of origin (Cox proportional hazards, Pearson correlation). We investigated clonal diversity of B-cell infiltrates through calculating B-cell receptor (BCR) repertoire sequence diversity. All statistical tests were two-sided. Results: High expression of T-cell and B-cell signatures predicted improved overall survival across many tumor types including breast, lung, and melanoma (breast CD8_T_Cells hazard ratio [HR] ¼ 0.36, 95% confidence interval [CI] ¼ 0.16 to 0.81, P ¼ .01; lung adenocarcinoma B_Cell_60gene HR ¼ 0.71, 95% CI ¼ 0.58 to 0.87, P ¼ 7.80E-04; melanoma LCK HR ¼ 0.86, 95% CI ¼ 0.79 to 0.94, P ¼ 6.75E-04). Macrophage signatures predicted worse survival in GBM, as did B-cell signatures in renal tumors (Glioblastoma Multiforme [GBM]: macrophages HR ¼ 1.62, 95% CI ¼ 1.17 to 2.26, P ¼ .004; renal: B_Cell_60gene HR ¼ 1.17, 95% CI ¼ 1.04 to 1.32, P ¼ .009). BCR diversity was associated with survival beyond gene segment expression in melanoma (HR ¼ 2.67, 95% CI ¼ 1.32 to 5.40, P ¼ .02) and renal cell carcinoma (HR ¼ 0.36, 95% CI ¼ 0.15 to 0.87, P ¼ .006). Conclusions: These data support existing studies suggesting that in diverse tissue types, heterogeneous immune infiltrates are present and typically portend an improved prognosis. In some tumor types, BCR diversity was also associated with survival. Quantitative genomic signatures of immune cells warrant further testing as prognostic markers and potential biomarkers of response to cancer immunotherapy.
The complex interplay between solid tumors and host immunity has been widely studied but remains incompletely understood. In multiple tumor types, tumor-infiltrating lymphocytes (TILs) have been associated with clinical outcomes (1) (2) (3) (4) (5) (6) (7) (8) . For example, CD8
þ TILs have been shown to be favorably prognostic in melanoma, colorectal, breast, ovarian, and non-small cell lung cancer. In selected tumors, it has been demonstrated that these CD8 þ TILs are able to specifically kill tumor cells (9, 10) .
Several schemas have been developed to leverage immune infiltration as a prognostic factor (11, 12) . Solid tumors are thought to cultivate an immunosuppressive microenvironment that promotes exhaustion of TILs and induction of a protumor, inflammatory wound-healing response (13) . This is supported by data that regulatory T-cells (T reg ), tumor-associated macrophages (TAMs), and/or myeloid-derived suppressor cells (MDSCs) predict worse outcomes in melanoma, renal cell carcinoma, breast, ovarian, bladder, prostate, and non-small cell lung cancer (14) (15) (16) . The wide impact and clinical relevance of the multifaceted tumor-associated immune response makes it critical to develop a more thorough understanding of this phenomenon. Next-generation sequencing and large-scale genomics have become critical to our understanding of human cancers. Through efforts such as The Cancer Genome Atlas (TCGA) Project, genomic data on a wide variety of tumors have become available. By combining diverse datasets, groupings both within and across tumor types have emerged (17) . This has deepened our understanding of distinctions within tumor types and highlighted similarities between previously distinct tumor types, such as identification of the "squamous" genomic subtype, which combines lung squamous, head and neck, and some bladder cancers into a single group (17, 18) . While many tumor types are thought to harbor prognostic TILs, the interplay between genomic subtype and the antitumor immune response has not been adequately explored.
Cancer immunotherapy has been pursued as an alternative or complement to cytotoxic chemotherapy and radiotherapy. Inhibition of the immune checkpoint proteins CTLA-4, PD-1, and PD-L1 reduces the ability of the tumor microenvironment to suppress host antitumor immunity (19) (20) (21) , and immune checkpoint inhibitors have shown clinical responses in diverse cancers (20) (21) (22) (23) (24) . As these and other immune-targeted therapies gain widespread clinical usage, a key question is identification of tumor characteristics that predict response. Evidence in melanoma and bladder cancer suggests that responders may harbor clonally restricted, antitumor TILs that are able to respond after immunosuppression has been lifted (23, 25) . In this work, we use mRNAseq data for a large number of diverse tumors to analyze the prevalence and prognostic relevance of tumor-immune infiltrates and evaluate the clonal diversity of tumor-infiltrating B-cells.
Methods

Datasets
The dataset used comprised mRNA-seq data from 3485 TCGA tumors (see TCGA Data Portal at https://tcga-data.nci.nih.gov/ tcga/, CGHub at https://cghub.ucsc.edu/), which was originally described in , with the following modifications (17) . AML samples were removed. Data for 329 melanoma samples were added (26) . All samples were assayed by mRNA-seq, as described by the TCGA Research Network (27) . Gene expression values were represented as RSEM data normalized within each sample to the upper quartile of total reads (37) . For gene signature and hierarchical clustering analyses, gene expression values were median-centered across all 3485 tumors. Genomic subtypes within tissue types and TCGA Pan-Cancer Cluster of Clusters Assignments (COCA) subtypes were obtained from previous publications of those TCGA tissue types (17, 18, (27) (28) (29) (30) (31) (32) (33) . No COCA subtype was assigned to melanoma samples, and thus melanoma was assigned to its own group in COCA subtype analyses (34) .
Gene Signatures and BCR Expression and Diversity
Several immune gene signatures were previously developed by unsupervised hierarchical clustering of mRNA-seq expression data for 728 breast tumor samples (35) . In addition to these, other tumor-infiltrating lymphocyte and macrophage gene 
Statistical Analysis
Gene signature expression levels were compared using one-way analysis of variance (ANOVA and statistically significant q-values were confirmed using the Kaplan-Meier estimator and log-rank testing of high-expression vs low-expression groups. All survival analyses were performed in R version 2.13.1 using the "survival" package (42, 43) . To assess the statistical significance of association between BCR diversity and survival, multivariable Cox proportional hazard models were constructed for each tumor tissue type where variables included BCR gene segment expression, diversity, and the expression*diversity interaction term. Separate models were fit using the expression term alone, and statistical significance was assessed by performing analysis of variance comparing the full and reduced models using the likelihood ratio test implemented in R (43) . A P value of less than .05 was considered statistically significant, and all statistical tests were two-sided.
Results
Genomic Signatures of Immune Infiltration in Human Cancer
To 
Prognostic Significance of Immune Infiltration Signatures
Univariate survival analyses for immune signature expression within tissue and COCA types are summarized in Table 1 and  Supplementary Table 1 (available online) , with hazard ratios provided in Supplementary Tables 2 and 3 (available .75E-04/6.04E-04, for B_Cell/B_Cell_60gene/LCK/Mac_CSF1). Signatures representing lymphocytes more consistently predicted overall survival than did other signatures; the lung adenocarcinoma, head and neck, breast, and endometrial tumor types showed consistent prognostic ability for lymphocyte signatures and a decreased association between survival and macrophage signatures. Interestingly, in clear cell renal cell carcinoma there was an association of B-cell signature expression with worse survival (eg, IGG_Cluster HR ¼ 1. 22, 95% CI ¼ 1.08 to 1.39, P ¼ .002). Macrophage-related signatures were less commonly prognostic though they were associated with worse survival overall and within GBM (eg, Macrophages HR ¼ 1.62, 95% CI ¼ 1.17 to 2.26, P ¼ .004).
Multivariable survival analyses of immune signatures were performed for each tumor tissue type individually, incorporating patient age, pathologic stage, and signature expression (Supplementary Tables 4-11 P ¼ .005/3.30E-04/.01 for head and neck/lung adenocarcinoma/ melanoma). GBM, ovarian, and endometrial tumors were excluded from multivariable analyses within tissue types, as pathologic staging data were not available.
Prognostic BCR Gene Segment Expression
Previous investigations of TILs have suggested that many tumors contain clonally restricted T-and/or B-cell infiltrates (44) (45) (46) , consistent with an antigen-driven response. As previously described, mRNA-seq data can be used to estimate the relative clonal diversity of B-cell populations and discover associations between specific BCR gene segment expression and improved survival (35) . Given our prior results that B-cell gene signature expression was more statistically significantly associated with improved OS than either T-cell gene signature expression or the classical clinical prognostic variables of age and lymph node involvement in breast cancer, and that specific BCR segments where expression was associated with OS Figure 4B ). For melanoma and head and neck squamous cell carcinoma, expression of the majority of BCR gene segments was associated with prolonged survival whereas in renal cell carcinoma and glioblastoma multiforme most segments were associated with reduced survival. There was a high degree of overlap of prognostic BCR segments across tumor types in which many BCRs were prognostic (melanoma, head and neck, glioblastoma, renal cell, lung adenocarcinoma, and breast). To understand the statistical significance of individual BCR gene segment expression, we assessed for each tumor type whether the number of prognostic BCR segments exceeded the number of prognostic genes expected by chance. To do this, we used a bootstrap resampling approach by randomly choosing a subset of genes of the same size as the number of total BCR gene segments (n ¼ 1000 resamplings) and considering as the null distribution the 95% confidence interval of the number of prognostic genes in the resampling dataset. For seven tumor types, the number of prognostic BCR segments exceeded the upper confidence interval of the null distribution ( Figure 4C ). ARTICLE Figure 5 shows BCR gene segment expression and sequence diversity for all samples and demonstrates the existence of a high-expression, low-diversity group composed mainly of a subset of melanoma, breast, head and neck, renal cell, and ovarian tumors. To test the association of restricted BCR diversity with survival, Cox proportional hazards models were built using BCRvariable gene segment expression, diversity, and the interaction term between expression and diversity. For each tissue type, this model was compared with a reduced model containing BCR gene segment expression as the sole variable. These models were compared using analysis of variance to assess whether including the diversity term in the full model provided a statistically significantly more robust explanation of variance than the expression term alone. This approach was used because B-cell gene segment expression was highly correlated with B-cell gene signature expression, which was statistically significantly associated with overall survival in multiple tumor types ( Table 1 ). The results of this analysis are shown in Figure 6 . The full model was found to be statistically significantly better at predicting survival in bladder, renal cell, and melanoma datasets. Decreased diversity was associated with improved survival in melanoma (HR ¼ 2.67, 95% CI ¼ 1.32 to 5.40, P ¼ .02). In contrast, decreased diversity was associated with diminished overall survival in renal cell carcinoma (HR ¼ 0.36, 95% CI ¼ 0.15 to 0.87, P ¼ .006).
ARTICLE
Discussion
Here we present several key aspects of a prognostically relevant immune response, determined from mRNA-seq data across a diverse set of human tumors. Patients with apparently beneficial tumor-immune infiltrates had high levels of immune signature expression for several cell types, including cytotoxic and helper T-cells, B/plasma cells, and macrophages/monocytes. Among these highly infiltrated tumors, a subset contained a highly expressed population of BCRs with lower sequence diversity. Squamous and basal-like COCA subtypes showed increased immune gene signature expression and prognostic significance. The fact that these subtypes were defined comprehensively by global gene expression, protein levels, DNA copy number, miRNA, and DNA methylation suggests that subtypedefining features may be responsible for the shared immunogenic phenotype.
Most investigations into the role of TILs in human tumors have focused on T-cells. Multiple studies have shown T-cell TILs to be associated with response to immune checkpoint inhibition and survival (23, (47) (48) (49) . This work adds to the growing body of literature identifying T-cell TILs as a positive prognostic feature. Less work has been done evaluating the role of B-cells in solid tumors, though CD20 expression has been associated with improved survival in breast and ovarian cancer (10, 50 ). Here we demonstrate that in all tumor types analyzed B-cell gene expression, including expression of BCR gene segments, was highly correlated with expression of T-cell genes. The strong correlation of immune signature expression across distinct immune cell types illustrates that the tumor-immune infiltrate is diverse but somewhat predicable and consistent, with a supportive role for B-cell TILs in the antitumor immune response. The addition of B-cell clonal diversity analysis represents a novel aspect of tumor-immune research and highlights the importance of B-cell TILs in diverse solid tumor types.
Our analysis of adaptive immune receptor repertoire diversity is limited by evaluation of BCR repertoires alone. We focused on the BCR for one major technical reason. The diversity estimate used here depends on the degree of sequence variation within the immunoglobulin-variable loci generated by somatic hypermutation. Because the TCR does not undergo somatic hypermutation, we are not able to measure TCR diversity using this approach. Our study is also limited by use of gene expression data to infer characteristics of the tumor-immune microenvironment without companion cellular assays, which were not obtainable from TCGA samples. Although the immune gene signatures reported here have been published and wellvalidated to correspond to specific cellular populations (12, 35) , we were unable to evaluate abundances of more complex immune cell phenotypes that may be important in tumor immunobiology and accessable via multiparameter IHC or flow cytometry. Nonetheless, our results are important in illustrating the power of immune gene signature and BCR repertoire analysis applied to a large and diverse RNA-seq dataset. It is unclear whether immunohistochemistry-based methods of interrogating the tumor-immune microenvironment, such as the Immunoscore (11), will outperform genomics methods for productive biomarker development.
For most of the tumor types tested, immune infiltrates were associated with improved survival; however, there were three tumor types that were exceptions: colorectal adenocarcinoma, clear cell renal cell carcinoma, and GBM. There are many studies indicating a beneficial role for TILs in human colorectal cancer (51) (52) (53) . The failure to detect these associations in TCGA data may have to do with the lack of adequate follow-up, low event rate, and low number of patients with mismatch repair gene mutations (54) . In renal cell carcinoma, high expression of B-cell signatures and decreased BCR diversity (consistent with an antigen-driven response) predicted poor survival. Previous work has suggested that this tumor type may contain abundant regulatory B-cells (B reg ), which may explain this finding. Immune infiltration appeared to predict worse outcomes in GBM as well. As in our data, infiltrating macrophages and/or microglia often represent a large proportion of immune infiltrates (55, 56) . The dominance of TAMs within the immune infiltrate of GBM is consistent with a negative clinical impact. In summary, for most solid tumor types, expression of immune gene signatures predicted a more favorable outcome. Analysis of potential clonal restriction suggests that in some tumors with heavy immune infiltration, B-cell clonal restriction adds prognostic information. This may be because of tumor antigen-driven expansion of specific B-cell clones. Not all tumor types show these common features, with counterexamples being GBM and clear cell renal cell carcinoma, where high immune infiltration predicted a worse outcome. Thus, measures of immune cell phenotypes, BCR (and potentially TCR) diversity, and tissue type or subtype are needed to correctly interpret, and likely act upon, these characteristics of the tumor microenvironment. High levels of pretreatment CD8
þ TILs have correlated with response to immune checkpoint inhibition in melanoma and bladder cancer (23, 47) . It will be important to test whether quantification of immune infiltrates using mRNA-seq predicts clinical response to these and other immunotherapeutic strategies going forward.
